Nanjing Chia-tai Tianqing Pharmaceutical

This Phase 2 trial tests NTQ5082, an oral drug, in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells break apart. The drug blocks a part of the immune system to prevent this destruction. The main goal is to see if it can raise h…

This Phase 1 trial is testing a new drug called NTB003 in 40 healthy adults to see if it is safe and how the body processes it. Participants will receive either NTB003 or a placebo in increasing doses. The study is an early step toward possibly treating thyroid eye disease, but i…